Generic Zuplenz Availability
Last updated on Apr 10, 2025.
Zuplenz is a brand name of ondansetron, approved by the FDA in the following formulation(s):
ZUPLENZ (ondansetron - film;oral)
-
Manufacturer: AQUESTIVE
Approval date: July 2, 2010
Strength(s): 4MG (discontinued) [RLD], 8MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zuplenz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Non-mucoadhesive film dosage forms
Patent 8,580,830
Issued: November 12, 2013
Inventor(s): Leichs; Christian et al.
Assignee(s): Labtec GmbH (N/A, DE); APR Applied Pharma Research S.A. (N/A, CH)Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.
Patent expiration dates:
- November 23, 2029✓
- November 23, 2029
-
Stabilized amine-containing actives in oral film compositions
Patent 9,095,577
Issued: August 4, 2015
Inventor(s): Myers Garry L. & Hariharan Madhu Sudan & Davidson Kevin & Sanghvi Pradeep
Assignee(s): MONOSOL RX, LLCThe present invention relates to compositions relating to films containing active pharmaceutical agents. In particular, the present invention relates to methods and systems useful for stabilizing amine-containing actives for dispersion in a film product.
Patent expiration dates:
- July 13, 2030✓
- July 13, 2030
More about Zuplenz (ondansetron)
- Zuplenz consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: 5HT3 receptor antagonists
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.